Explore

Trendline Trendline
Senticell Secures Seed Funding to Advance Red Blood Cell-Based Liquid Biopsy Platform for Cancer Detection

Senticell Secures Seed Funding to Advance Red Blood Cell-Based Liquid Biopsy Platform for Cancer Detection

Senticell Secures Seed Funding to Advance Red Blood Cell-Based Liquid Biopsy Platform for Cancer Detection
Rapid Read Rapid Read
Fred Hutch Cancer Center Leads $15 Million National Clinical Trial for Older Adults with Acute Myeloid Leukemia

Fred Hutch Cancer Center Leads $15 Million National Clinical Trial for Older Adults with Acute Myeloid Leukemia

Fred Hutch Cancer Center is spearheading a new national clinical trial initiative, backed by a $15 million grant from the Patient-Centered Outcomes Research Institute (PCORI). This initiative aims to identify the most effective treatment strategies for older adults diagnosed with acute myeloid leukemia (AML), an aggressive and rapidly progressing blood cancer. The clinical trial program, led by Dr. Mohamed Sorror, will involve an 18-center U.S. consortium. It will compare stem cell transplantation with non-transplant therapies for AML patients after they achieve remission. This research is crucial given the challenges in treating AML in older populations. Additionally, Fred Hutch researchers, including Dr. Andrew C. Hsieh and Dr. Rashmi Mishra, have identified a molecular switch that allows prostate cancer to evade therapy, opening new avenues for treatment. Separately, Dr. David MacPherson and Dr. Gavin Ha received a $1.5 million grant to develop SCLCpheno-seq, a liquid biopsy for small cell lung cancer (...
Trendline Trendline
Roche Secures $1.5 Billion Oncology Partnership with Simcere Zaiming for B-Cell Disease Treatment

Roche Secures $1.5 Billion Oncology Partnership with Simcere Zaiming for B-Cell Disease Treatment

Roche Secures $1.5 Billion Oncology Partnership with Simcere Zaiming for B-Cell Disease Treatment
Rapid Read Rapid Read
European Investment Bank Invests €100 Million in Elekta's Radiotherapy Solutions to Advance Cancer Treatment

European Investment Bank Invests €100 Million in Elekta's Radiotherapy Solutions to Advance Cancer Treatment

The European Investment Bank (EIB) has announced a €100 million investment in Elekta, a Swedish health-tech company specializing in radiotherapy solutions. This significant funding aims to bolster Elekta's research and development efforts in advanced cancer and neurological condition treatments. Elekta's technologies are currently utilized to treat over 2 million patients globally each year for various conditions, including brain, breast, kidney, lung, pancreatic, and prostate cancers, as well as essential tremor and certain forms of epilepsy. The company plans to allocate approximately €200 million to its research program between 2026 and 2029, with the majority of this work concentrated in Sweden and the Netherlands. The EIB's loan will cover up to half of this planned investment, focusing on areas such as radiotherapy, radiosurgery, brachytherapy, and software for therapy planning and delivery.
Rapid Read Rapid Read
Dr. Tobias Janowitz Appointed Director of Cancer Research at Feinstein Institutes, Northwell Health

Dr. Tobias Janowitz Appointed Director of Cancer Research at Feinstein Institutes, Northwell Health

Dr. Tobias Janowitz has been appointed as the new director of the Institute of Cancer Research at the Feinstein Institutes for Medical Research. In addition to this role, he will serve as the Robert and Janet Perro Professor in Cancer Research and director of Translational Cancer Research at Northwell Health's Cancer Institute. Dr. Janowitz will also continue to lead his established research program at Cold Spring Harbor Laboratory (CSHL) Cancer Center, fostering a closer strategic affiliation between CSHL and Northwell. His research, spanning over two decades, focuses on understanding the mechanisms driving cancer progression, particularly the metabolic, neuroendocrine, and immune circuits that influence disease progression and therapeutic response. He has investigated how systemic stress induced by tumors alters energy metabolism, elevates stress hormones, and weakens the immune system, contributing to cancer cachexia, a severe wasting syndrome. As a gastrointestinal oncologist, Dr. Janowitz aims to rede...
Rapid Read Rapid Read
Advanced Imaging Technique Reveals Immune Cell Metabolic States in Blood Samples

Advanced Imaging Technique Reveals Immune Cell Metabolic States in Blood Samples

Scientists at the Morgridge Institute for Research have developed an advanced imaging technique, Optical Metabolic Imaging (OMI), capable of characterizing the metabolic activity within individual immune cells from peripheral blood mononuclear cells (PBMCs). This method, detailed in Biophotonics Discovery, offers a non-destructive way to assess immune cell function, providing more detailed information than traditional cell counts. PBMCs, which are predominantly immune cells, are crucial for understanding disease progression and treatment effects in conditions like certain cancers and immune disorders. The OMI technique utilizes two long-wavelength photons to excite the inherent fluorescence of cell metabolism products, allowing researchers to identify whether PBMCs are metabolically active or quiescent without damaging the cells or requiring chemical labels. This approach achieved 93% accuracy in identifying metabolic states two hours after cell stimulation and could specifically identify quiescent and act...
Trendline Trendline
Lighteum Medical Appoints Gaurav Agarwal as New Chief Executive Officer

Lighteum Medical Appoints Gaurav Agarwal as New Chief Executive Officer

Lighteum Medical Appoints Gaurav Agarwal as New Chief Executive Officer
Rapid Read Rapid Read
Aging Clocks Show Promise for Longevity Interventions but Face Reliability Challenges

Aging Clocks Show Promise for Longevity Interventions but Face Reliability Challenges

Aging clocks, developed using machine learning techniques on biological data, are designed to predict age-related conditions and mortality risk. These clocks utilize various data types, including omics data, clinical chemistry results from blood tests, and imaging data. When applied to individuals, a higher predicted age compared to chronological age often correlates with increased mortality risk and the presence of age-related conditions. The primary goal for these aging clocks is to provide a rapid assessment tool for novel longevity interventions, potentially eliminating the need for lengthy, decade-spanning clinical trials. However, a significant challenge remains: ensuring the reliability of these clocks in assessing the efficacy of new interventions. There is currently no direct, well-mapped connection between the data used to derive these clocks and the underlying mechanisms of aging, making it difficult to predict whether a given clock will accurately estimate the effects of a treatment without ext...
Trendline Trendline
N-Power Medicine Secures $32M Series B Funding to Expand Community Oncology Research

N-Power Medicine Secures $32M Series B Funding to Expand Community Oncology Research

N-Power Medicine Secures $32M Series B Funding to Expand Community Oncology Research
Rapid Read Rapid Read
IU Health Launches Theranostics Center of Excellence to Expand Personalized Cancer Treatments

IU Health Launches Theranostics Center of Excellence to Expand Personalized Cancer Treatments

Indiana University Health has announced the establishment of the IU Health Theranostics Center of Excellence, a new program designed to provide highly personalized cancer treatment. This initiative integrates advanced medical imaging, precision diagnostics, and image-targeted therapies. The program aims to improve patient outcomes by accelerating access to precision medicine across Indiana. It builds upon existing strengths within IU Health and the IU School of Medicine, leveraging their expertise in precision genomics and clinical trial infrastructure. The center will initially focus on FDA-approved precision-targeted therapies for prostate and neuroendocrine cancers, with plans to expand access to investigational treatments for other cancer types. The launch was made possible by a $20 million gift commitment from Sarah and John Lechleiter and Deborah and Randall Tobias, which was matched by IU Health, bringing the total investment to $40 million. This funding established the Tobias-Lechleiter Institute f...
Trendline Trendline
Digital Twins Revolutionize Drug Development by Enhancing Simulation and Predictive Capabilities

Digital Twins Revolutionize Drug Development by Enhancing Simulation and Predictive Capabilities

Digital Twins Revolutionize Drug Development by Enhancing Simulation and Predictive Capabilities
Rapid Read Rapid Read
Win-Win Initiative Calls for Global Action to Make Cancer Care Affordable

Win-Win Initiative Calls for Global Action to Make Cancer Care Affordable

The Win-Win: Game-Changing Global Cancer Care movement is advocating for a coordinated international response to address the growing disparity between advancements in cancer treatment and its affordability. Despite scientific progress, millions worldwide, including a significant portion of U.S. patients, cannot access effective cancer care due to high costs. The initiative highlights that over 70% of cancer patients in low- and middle-income countries lack access, and in the United States, approximately 40% of patients are primarily concerned about treatment costs and potential family bankruptcy. The movement proposes seven key actions to improve affordability, including bringing overlooked cost-saving evidence into practice, making affordability a major research priority, and ensuring critical safety information is more accessible. It also aims to confront the waste and misallocation of billions of dollars in cancer care and turn scientific evidence into persistent global advocacy. The initiative emphasiz...